See more : Luvu Brands, Inc. (LUVU) Income Statement Analysis – Financial Results
Complete financial analysis of CervoMed Inc. (CRVO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of CervoMed Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- CFECAPITAL, S. De R.L. De C.V. (FCFE18.MX) Income Statement Analysis – Financial Results
- Intelicanna Ltd (INTL.TA) Income Statement Analysis – Financial Results
- Aptamer Group plc (APTA.L) Income Statement Analysis – Financial Results
- boohoo group plc (BHHOF) Income Statement Analysis – Financial Results
- Toung Loong Textile Mfg.Co.,Ltd. (4401.TWO) Income Statement Analysis – Financial Results
CervoMed Inc. (CRVO)
About CervoMed Inc.
CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of drug treatments for neurodegenerative diseases. It develops neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, and brain stroke recovery. The company is based in Boston, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 1999 | 1998 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 7.14M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 71.67K | 374.54K | 570.48K | 40.19K | 0.00 | 40.19K | 308.76K | 0.00 | 0.00 | 26.94M | 27.91M |
| Cost of Revenue | 8.44M | 1.34M | 93.42K | 103.17K | 97.92K | 110.37K | 67.98K | 25.34K | 8.27K | 566.26K | 675.76K | 235.80K | 2.31M | 210.39K | 47.20K | 24.68K | 134.15K | 0.00 | 0.00 | 26.89M | 23.60M |
| Gross Profit | -1.29M | -1.34M | -93.42K | -103.17K | -97.92K | -110.37K | -67.98K | -25.34K | -8.27K | -566.26K | -604.09K | 138.74K | -1.74M | -170.20K | -47.20K | 15.51K | 174.61K | 0.00 | 0.00 | 48.06K | 4.31M |
| Gross Profit Ratio | -18.11% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -842.91% | 37.04% | -304.68% | -423.51% | 0.00% | 38.59% | 56.55% | 0.00% | 0.00% | 0.18% | 15.45% |
| Research & Development | 8.44M | 1.34M | 8.50M | 9.43M | 6.62M | 5.75M | 5.09M | 6.25M | 3.88M | 2.86M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 465.91K | 300.00K |
| General & Administrative | 6.52M | 2.14M | 7.45M | 6.44M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 6.70M | 10.01M | 6.77M | 0.00 | 950.75K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 6.52M | 2.14M | 7.45M | 6.44M | 4.83M | 6.17M | 6.19M | 8.59M | 2.52M | 3.91M | 7.31M | 6.70M | 10.01M | 6.77M | 992.50K | 950.75K | 2.57M | 41.90K | 92.20K | 6.42M | 3.20M |
| Other Expenses | 0.00 | -2.39M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 5.23M | 4.69M | 699.67K | -1.91M | 1.29M | -490.01K | 0.00 | 0.00 | -6.84M | 813.03K |
| Operating Expenses | 14.96M | 3.48M | 15.94M | 15.87M | 11.45M | 11.92M | 11.28M | 14.85M | 6.40M | 6.77M | 7.31M | 11.93M | 14.69M | 7.47M | 2.90M | 2.24M | 3.06M | 41.90K | 92.20K | 48.06K | 4.31M |
| Cost & Expenses | 14.96M | 3.48M | 16.04M | 15.97M | 11.55M | 12.03M | 11.35M | 14.87M | 6.41M | 7.34M | 7.98M | 12.17M | 17.00M | 7.68M | 2.95M | 2.26M | 3.19M | 41.90K | 92.20K | 34.16M | 27.91M |
| Interest Income | 219.43K | 62.23K | 137.49K | 114.26K | 0.00 | 151.65K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 102.44K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 587.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.92M | 29.69K | 313.12K | 273.50K | 228.29K | 167.89K | 30.54K | 81.39K | 122.92K | 186.49K | 162.16K | 6.20K | 2.66K | 0.00 | 500.00K |
| Depreciation & Amortization | 5.64M | 3.48M | 93.42K | 103.17K | 97.92K | 110.37K | 67.98K | 25.34K | 8.27K | 566.26K | 675.76K | 164.04K | 119.81K | 49.67K | 47.20K | 55.85K | 58.03K | 0.00 | 0.00 | 386.99K | -200.00K |
| EBITDA | -2.17M | 0.00 | -24.45M | -15.76M | -11.37M | -18.70M | 566.01K | -18.35M | -6.40M | -16.33M | -1.55M | -6.65M | -22.49M | -8.28M | -3.23M | -1.15M | -2.45M | -41.90K | -92.20K | -6.84M | 813.03K |
| EBITDA Ratio | -30.40% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -2,168.22% | -1,774.94% | -3,941.53% | -20,599.03% | 0.00% | -2,865.27% | -792.06% | 0.00% | 0.00% | -25.38% | 2.91% |
| Operating Income | -7.81M | -3.48M | -16.04M | -15.97M | -11.55M | -12.03M | -11.35M | -14.87M | -6.41M | -7.34M | -7.91M | -11.79M | -16.43M | -7.64M | -2.95M | -2.22M | -2.88M | -41.90K | -92.20K | -7.22M | 613.03K |
| Operating Income Ratio | -109.35% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -11,039.83% | -3,148.34% | -2,879.94% | -19,002.60% | 0.00% | -5,529.81% | -934.14% | 0.00% | 0.00% | -26.82% | 2.20% |
| Total Other Income/Expenses | 5.64M | -2.33M | -8.50M | 114.25K | 85.30K | -6.78M | 8.93M | -3.53M | -313.12K | -9.83M | 5.45M | 4.94M | -6.21M | -772.65K | -452.64K | 2.22M | 218.50K | -6.20K | -2.66K | -836.31K | -613.03K |
| Income Before Tax | -2.17M | -5.80M | -24.54M | -15.86M | -11.47M | -18.81M | -2.42M | -18.40M | -6.72M | -17.17M | -2.46M | -6.85M | -22.64M | -8.41M | -3.40M | 0.00 | -2.67M | -48.10K | -94.86K | -8.06M | 0.00 |
| Income Before Tax Ratio | -30.40% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -3,429.68% | -1,828.85% | -3,967.89% | -20,925.14% | 0.00% | 0.00% | -863.38% | 0.00% | 0.00% | -29.92% | 0.00% |
| Income Tax Expense | 0.00 | -3.48M | -443.89K | -1.68M | 332.89K | -437.29K | -1.06M | -364.80K | 0.00 | -2.82M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.09M | 0.00 | 0.00 | 0.00 | 0.00 | -200.00K |
| Net Income | -2.17M | -5.80M | -24.10M | -14.19M | -11.80M | -18.37M | -1.36M | -18.04M | -6.72M | -14.35M | -2.46M | -6.87M | -22.64M | -8.41M | -3.40M | -2.09M | -2.67M | -48.10K | -94.86K | -8.06M | 200.00K |
| Net Income Ratio | -30.40% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -3,438.61% | -1,833.94% | -3,967.89% | -20,925.14% | 0.00% | -5,208.56% | -863.38% | 0.00% | 0.00% | -29.92% | 0.72% |
| EPS | -0.82 | -11.20 | -18.51 | -19.76 | -131.95 | -424.93 | -123.33 | -1.98K | -28.85K | -11.29K | -11.20K | -93.24K | -295.21K | -150.17K | -66.32K | -42.72K | -61.40K | -456.62K | -900.63K | 0.00 | 0.00 |
| EPS Diluted | -0.82 | -11.20 | -18.51 | -19.76 | -131.95 | -424.93 | -120.35 | -1.98K | -28.85K | -11.29K | -11.20K | -93.24K | -295.21K | -150.17K | -66.32K | -42.72K | -61.40K | -456.62K | -900.63K | 0.00 | 0.00 |
| Weighted Avg Shares Out | 2.66M | 518.14K | 1.30M | 717.76K | 89.42K | 43.23K | 11.06K | 9.10K | 232.88 | 1.27K | 235.25 | 79.00 | 78.00 | 56.00 | 51.28 | 49.00 | 43.42 | 0.11 | 0.11 | 0.00 | 0.00 |
| Weighted Avg Shares Out (Dil) | 2.66M | 518.14K | 1.30M | 717.76K | 89.42K | 43.23K | 11.34K | 9.10K | 232.88 | 1.27K | 235.25 | 79.00 | 78.00 | 56.00 | 51.28 | 49.00 | 43.42 | 0.11 | 0.11 | 0.00 | 0.00 |
CervoMed to Participate in Upcoming Investor Conferences
BOSTON, March 28, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced that Company's Management will participate in the following three investor conferences during the month of...
CervoMed Announces Up to $149.4 Million Private Placement Financing Joined by Leading Healthcare Investors
Funding from new investors, including RA Capital Management, Armistice Capital, Special Situations Funds and Soleus Capital
CervoMed Announces Presentation of Biomarker Data from the AscenD-LB Phase 2a Trial and Preclinical Data Supporting Potential of Neflamapimod in Tau-Mediated Disease at AD/PD ™ 2024
- Neflamapimod led to significant reduction compared to placebo in plasma levels of glial fibrillary acidic protein (GFAP)
CervoMed to Participate in the BIO CEO and Investor Conference
BOSTON, Feb. 21, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for degenerative diseases of the brain, today announced that Company's Management will present at the BIO CEO and Investor Conference on...
CervoMed Publishes Positive Results from AscenD-LB Phase 2a Trial in Peer-Reviewed Journal that Supports the Therapeutic Potential of Neflamapimod in Dementia with Lewy Bodies
-Integrated summary of all previously published Phase 2a clinical results, together with the first peer reviewed publication of EEG and MRI results, substantially derisk the ongoing RewinD-LB Phase 2b trial of neflamapimod in dementia with Lewy bodies -
CervoMed Announces Appointment of Industry Leader Joshua Boger, Ph.D., as Chair of the Board
Dr. Boger is the founder, and retired CEO and Board Chair, of Vertex Pharmaceuticals CervoMed on track to complete enrollment in 1H 2024 in its RewinD-LB Phase 2b clinical trial evaluating neflamapimod in patients with dementia with Lewy bodies; topline...
CervoMed to Participate in the Emerging Growth Conference 67
BOSTON, Feb. 05, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for degenerative diseases of the brain, today announced that Company's Management will provide a corporate update at the Emerging Growth Conference...
CervoMed to Participate in the Emerging Growth Conference 66
BOSTON, Jan. 05, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for degenerative diseases of the brain, today announced that Company's Management will provide a corporate update at the Emerging Growth Conference...
CervoMed Reports Third Quarter 2023 Financial Results and Business Highlights
Dosed first patient in Phase 2b RewinD-LB study evaluating neflamapimod in patients with dementia with Lewy bodies (DLB) Multiple peer-reviewed journal publications and a conference presentation inform on the potential of neflamapimod in DLB and probability of success in optimized...
CervoMed Announces Oral Presentation at CTAD 2023 Highlighting Learnings from Phase 2a Which Optimized the Design of the Phase 2b Clinical Study of Neflamapimod in Dementia with Lewy Bodies
With incorporation of key learnings, Phase 2b has >95% (approaching 100%) statistical power to meet its primary endpoint: change in Clinical Dementia Rating Sum-of-Boxes (CDR-SB) vs. placebo New data included in the presentation show that in patients without Alzheimer's-related co-pathology,...
Source: https://incomestatements.info
Category: Stock Reports